Company 1 6 月, 2021

“Easy access, strict management, heavy penalties” The newly revised “Regulations on the Supervision and Administration of Medical Devices” comes into effect today

On June 1, the newly revised "Regulations on the Supervision and Administration of Medical Devices" (hereinafter referred to as the "New Regulations") were officially implemented. Registrants will bear corresponding…

On June 1, the newly revised “Regulations on the Supervision and Administration of Medical Devices” (hereinafter referred to as the “New Regulations”) were officially implemented. Registrants will bear corresponding legal responsibilities for the product quality of the entire life cycle of medical devices. Industry understanding summarizes this as “lenient access, strict management, and heavy penalties.” On the afternoon of May 31, the State Food and Drug Administration issued an announcement on matters related to the implementation of the new “Regulations”, stipulating that starting from June 1, 2021, all enterprises and medical device research and development institutions that hold a medical device registration certificate or have gone through the filing of Class I medical devices must perform the obligations of medical device registrants and filers respectively in accordance with the provisions of the new “Regulations”, strengthen the quality management of the entire life cycle of medical devices, and bear responsibility for the safety and effectiveness of medical devices throughout the entire process of development, production, operation, and use.

       据国家药监局介绍,配套规章、规范性文件和技术指导原则等正在组织制修订,将按照程序陆续发布。

     《医疗器械监督管理条例》2000年颁布以来,于2014年2月12日国务院第39次常务会议修订通过;本次修订于2020年12月21日国务院第119次常务会议修订通过。


Establish the registrant system as the core system for medical device supervision

  本次修订实施后,医疗器械注册人备案人制度将作为医疗器械监管核心制度在全国范围内推行。国家药监局副局长徐景和日前表示,全面实施医疗器械注册人备案人制度是新《条例》的核心内容,是推动医疗器械产业创新发展、高质量发展的重要举措。

  注册人制度是指医疗器械注册申请人(以下简称“申请人”)提出申请,其样品委托受托人生产并获得《医疗器械注册证》后,成为注册人;注册人委托受托人生产产品并以注册人名义上市,对医疗器械全生命周期产品质量承担相应法律责任的制度。

  据了解,医疗器械注册人制度试点工作此前持续开展。2020年22个省、自治区、直辖市共计552个产品按照医疗器械注册人制度试点获准上市,较2019年底(93项)增长493%。试点工作取得预期效果,批准产品数量大幅度增长,注册形式覆盖全面。国药控股股份有限公司党委书记、董事长于清明认为,医疗器械注册人制度有利于优化资源配置,促进产业集中,提升竞争力,同时有利于鼓励创新,缩短产品上市周期,并推动供给侧结构性改革,淘汰“低、小、散”。

Those who meet the regulations are exempt from clinical evaluation

  国家药监局公告称,自2021年6月1日起,医疗器械注册申请人、备案人根据新《条例》规定开展临床评价。符合新《条例》规定的免于临床评价情形的,可以免于临床评价;进行临床评价,可以根据产品特征、临床风险、已有临床数据等情形,通过开展临床试验,或者通过对同品种医疗器械临床文献资料、临床数据进行分析评价,证明医疗器械安全、有效;已有临床文献资料、临床数据不足以确认产品安全、有效的医疗器械,应当开展临床试验。在免于临床评价的相关文件发布实施前,免于进行临床评价医疗器械目录参照现行免于进行临床试验医疗器械目录执行。

Step by step implementation of the unique identification system for medical devices, products will have “ID cards”

In addition, the new “Regulations” propose that the state will implement a unique identification system for medical devices step by step according to the category of medical device products to achieve traceability of medical devices. According to the relevant person in charge of the Liaoning Provincial Food and Drug Administration, the unique identification of medical devices is the “ID card” of medical device products and the “international language” of medical devices. As a common international practice, countries and regions such as Europe and the United States are actively promoting this system. The medical device unique identification system consists of a medical device unique identification, a data carrier and a database. Each medical device is given an ID card to achieve transparency and visualization in all aspects of production, operation and use, and improve product traceability. Establishing a unique identification system can strengthen the supervision of the entire life cycle of medical devices, and can also build big data for medical device supervision, so that the sources of medical devices can be traced, their whereabouts can be traced, and responsibilities can be held accountable, and smart supervision can be realized.

Encourage innovation and prioritize review and approval of innovative medical devices

  本次《医疗器械监督管理条例》的修订,把“创新”摆在了关键位置,增加了若干鼓励创新的内容,例如要求“对在医疗器械的研究与创新方面做出突出贡献的单位和个人,按照国家有关规定给予表彰奖励。”新《条例》强调:国家制定医疗器械产业规划和政策,将医疗器械创新纳入发展重点,对创新医疗器械予以优先审评审批,支持创新医疗器械临床推广和使用,推动医疗器械产业高质量发展。近些年,随着审评审批制度改革的深化,持续鼓励医疗器械创新发展的举措不断显效。根据国家药监局发布的《2020年度医疗器械注册工作报告》,2020年我国批准了冠脉血流储备分数计算软件等26个创新医疗器械上市,截至2020年底获批上市创新医疗器械达到99个;按照优先医疗器械审批程序,批准遗传性耳聋基因检测试剂盒等15个医疗器械上市。

In addition, regarding the investigation and punishment of medical device violations, the State Food and Drug Administration emphasized that if medical device violations occurred before June 1, 2021, the pre-revised “Regulations” shall apply. However, if it is deemed not illegal or the penalty is lighter according to the new “Regulations”, the new “Regulations” will apply.

Back to News